Sponsored by LightAI Inc.
(CBOE: ALGO)
Please read the Disclaimers, FWD Looking Statements and Disclosures
Consider yourself lucky if you ever sat across from Peter Whitehead, a man who’s quietly changed the lives of millions.
If his name doesn’t ring a bell, his previous invention might.
It’s called the VELScope, a revolutionary tool for detecting oral cancer, used in more than 50-million clinical examinations around the world.
He’s a five-time winner of the American Dental Association’s ‘Best of Class’ Technology Award.
Now, Peter is focused on something even bigger—something that could redefine healthcare globally.
He placed his phone on the table, opened an app, and said: “What if diagnosing an illness like Strep A took less time than sending a text?”.
Introducing LightAI (ALGO:CBOE), his latest brainchild.
And what it offers isn’t just faster finding—it’s a revolution in how we approach infectious diseases.
The Problem That Costs Millions of Lives Every Year
In the United States, for every 10 sore throats treated, six result in antibiotic prescriptions. Only two or three of those are bacterial infections.
This over-prescription feeds a global health crisis: antimicrobial resistance.
- The World Health Organization has called it one of the top five threats to humanity.
Strep A, the initial target for Light AI’s technology, infects 287 million people every year. If you have kids, there’s a good chance you had a scare or two. Maybe even during your own childhood.
It’s a silent killer, particularly in low-resource countries where diagnostic tools are scarce. The current system is painfully inefficient: a doctor’s visit, lab tests, and a wait for results. For many, that wait costs precious time—and sometimes, lives.
But what if the solution didn’t involve a lab? What if it lived on the one device nearly everyone already carries?
The Solution No One Saw Coming
LightAI (ALGO:CBOE) is developing technology aiming to transform any smartphone into a testing powerhouse.
Here’s how it works:
You open the app, follow a few simple steps, and snap a photo of the patient’s throat. Within seconds, the AI analyzes the image, providing a finding.
No swabs, no labs, no waiting—just actionable results.
What Makes This So Unique…
- High-Level Accuracy: Light AI’s platform is backed by a proprietary library of over 300,000 images, delivering a negative predictive value (NPV) of 100%.
- Global Scalability: No hardware needed, just a smartphone. This means the technology can scale rapidly, especially in underserved markets.
- Time-Saving Efficiency: A result in under a minute, compared to hours or even days with traditional methods.
Note: Regulatory approvals and third-party verification are required before commercial deployment.
Source – January 2025 presentation.
But what makes Light AI truly unique is its scalability.
Through a partnership with TC4A (Tech Care 4 All), the company is poised to bring its technology to lower-income countries, addressing some of the world’s most pressing public health challenges.
LightAI Wants a Piece of a $65 Billion Market
Analysts predict that the global point-of-care diagnostics market is expected to hit $65 billion by 2027. LightAI is looking to make a dent in that and attempt to disrupt it.
Unlike traditional diagnostics companies that rely on expensive proprietary hardware, LightAI leverages the one tool everyone already owns: a smartphone.
And the opportunity isn’t limited to affluent markets…
In many developing countries, where access to healthcare infrastructure is limited, this technology could mean the difference between life and death.
- Light AI has already secured over $18 million in funding and built partnerships with industry giants like Johnson & Johnson and the CDC.
The team includes seasoned veterans in AI, healthcare, and regulatory compliance—names you trust when betting on the future.
Timing Is Everything
LightAI is public under the ticker “ALGO” on the Canadian markets.
Peter Whitehead’s experience with the VELScope highlights his background in medical technology innovation.
Weighing the Risks—and the Rewards
Let’s be clear: Light AI is not without risks.
It’s transitioning from private to public, and the healthcare diagnostics market is competitive.
However, these risks are mitigated by the company’s proven technology, its world-class team, and its razor-sharp focus on execution.
The healthcare industry is starved for innovation, and Light AI offers something that’s as transformative as it is timely.
Every so often, an opportunity comes along with the potential that doesn’t just change an industry—it could create a path to a new standard.
You can find out more at www.light.ai.
This is a company we have our eye on and follow closely.
Regards,
The Katusa Research Special Situations Team
Sources:
- Light.AI Investor Presentation dated October 29, 2024
- www.light.ai
- LightAI Long Form Prospectus
- 287 Million Strep A Infections
IMPORTANT DISCLAIMER & DISCLOSURES
Investing in stocks is HIGH RISK. You could lose all of your investment.
Katusa Research, as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.
Please do not rely on the information presented by Katusa Research as personal investment advice.
If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor. The communications from Katusa Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.
LightAI Inc. is a paid sponsor of this report.
The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.
Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Katusa Research nor any employee of Katusa Research is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. Katusa Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.
HIGHLY BIASED: In our role, we aim to highlight specific companies for your further investigation; however, these are not stock recommendations, nor do they constitute an offer or sale of the referenced securities. Katusa Research partner company, New Era Publishing Inc. has received cash compensation in the amount of seventy-five thousand dollars from LightAI Inc. and is thus extremely biased. It is crucial that you conduct your own research prior to investing. This includes reading the companies’ SEDAR and SEC filings, press releases, and risk disclosures. The information contained herein regarding LightAI Inc. has been derived from its SEDAR+ and SEC filings, including scientific and technical information. Information regarding the projects underlying LightAI Inc.’s interests has been derived from the publicly available disclosure of the underlying operators and owners, including where referenced herein.
Katusa Research, and its directors, employees, and members of their households own shares of LightAI Inc (ALGO:CBOE) and stand to benefit from any increase in the stock price. However, Katusa Research is extremely biased since this is a sponsored editorial.
HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.
NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Katusa Research, and all partners, members, and affiliates harmless in any event or claim. While Katusa Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Katusa Research is not obligated to update, correct, or revise the information post-publication.
FORWARD-LOOKING STATEMENTS: Certain information presented may contain or be considered forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in these statements. There can be no assurance that any such statements will prove to be accurate, and readers should not place undue reliance on such information. These statements are subject to known and unknown risks including those set forth in LightAI Inc.’s most recent annual information form and other public filings available at www.sedarplus.ca and www.sec.gov. Neither Katusa Research nor LightAI Inc. undertake any obligations to update the information presented or to ensure that such information remains current and accurate, except as required under applicable law.
